| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 24, 2026
Exclusive agreement expands Medtronic's comprehensive pain interventions portfolio, increases treatment options for patients living with chronic pain GALWAY, Ireland, March 24, 2026 /PRNewswire/...
Feb 17, 2026Cardiovascular portfolio up 11% year-over-year; Cardiac Ablation Solutions grew 80% on strength of pulsed field ablation portfolio GALWAY, Ireland, Feb. 17, 2026 /PRNewswire/ -- Medtronic plc...
Jan 23, 2026First-of-its-kind, rotation-free single-shot PFA catheter supported by strong safety and efficacy data adds to the groundbreaking Affera family of technologies in Europe Successful completion of...
Nov 18, 2025Cardiac Ablation Solutions growth of 71% on strength of pulsed field ablation (PFA) portfolio; Raising FY26 revenue and EPS guidance GALWAY, Ireland, Nov. 18, 2025 /PRNewswire/ -- Medtronic plc...
Aug 19, 202511th quarter in a row of mid-single digit organic revenue growth; Poised to accelerate growth GALWAY, Ireland, Aug. 19, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in...
May 21, 2025Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation GALWAY, Ireland, May 21, 2025 /PRNewswire/ -- Medtronic...
-
May 21, 2025
Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only...
-
Apr 26, 2025
One-year clinical trial data for the next-generation, investigational, Sphere-360™ single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal Afib...
Feb 18, 2025Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation GALWAY, Ireland, Feb. 18, 2025 /PRNewswire/...
Nov 19, 2024Delivering on commitments, executing ahead of expectations, and raising guidance Innovation driving sustained growth across many franchises: TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and...
-
Oct 28, 2024
Company commits to advancing clinical data for Symplicity™ with the SPYRAL Gemini clinical trial and expansion of the GSR-DEFINE clinical trial GALWAY, Ireland and WASHINGTON, Oct. 28, 2024...
Oct 24, 2024First-of-its-kind, all-in-one HD-mapping and dual energy (pulsed field and radiofrequency) ablation catheter Highly anticipated by electrophysiologists for its innovation and demonstrated safety...
-
Sep 27, 2024
APHRS: New data confirm robust long-term durability and highly efficient procedure performed without fluoroscopy Successful launch in Japan follows recent reimbursement approval Approvals across...
Aug 20, 2024Product innovation driving growth across diversified health tech portfolio, including Automated Insulin Delivery, Transcatheter Aortic Valve Replacement, Pulsed Field Cardiac Ablation, Pain...
May 23, 2024Broad-based, durable growth across the company, including Cranial & Spinal Technologies, Diabetes, Cardiac Pacing, Surgical, and Structural Heart; gaining momentum as company enters new product...
-
May 17, 2024
HRS late breaking data: SPHERE Per-AF trial demonstrates novel all-in-one system delivers exceptional results, plus increased efficiency and improved quality of life DUBLIN and BOSTON, May 17,...
Apr 8, 2024EHRA late-breaking data: Results highlight efficacy, safety, and durability of the novel PFA catheter that is fully integrated with Affera™ Mapping and Ablation System DUBLIN and BERLIN, April...
Feb 20, 2024Delivers on commitments with strong growth in Core Spine, Cardiac Surgery, Structural Heart, Cardiac Pacing, and across many international markets; Diabetes increases double digits as U.S....
Dec 13, 2023Safe, efficient, and effective treatment for both paroxysmal and persistent atrial fibrillation DUBLIN, Dec. 13, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare...
Nov 21, 2023Solid execution results in mid-single digit revenue growth, driven by broad-based strength across multiple businesses and geographies; Major innovative product approvals; Raises fiscal year...
Aug 22, 2023Broad strength across businesses and geographies results in mid-single digit revenue growth, driven by execution, innovation, and improved underlying fundamentals DUBLIN, Aug. 22, 2023...
May 25, 2023Mid-single digit fourth quarter revenue growth exceeded expectations on broad-based strength across the company DUBLIN, May 25, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced...
Mar 15, 2023First of its kind, all-in-one Sphere-9™ Catheter with pulsed field ablation, radiofrequency, and high density mapping integrated with intuitive mapping and navigation platform DUBLIN, March 15, 2023
Mar 6, 2023ACC.23/WCC late-breaking data: PULSED AF, one of the most rigorously executed PFA clinical studies to date, exceeds safety and efficacy performance goals in the treatment of paroxysmal and...
Feb 21, 2023Delivers top and bottom line ahead of expectations, with strength in Cardiovascular and Neuroscience portfolios DUBLIN, Feb. 21, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced...
Dec 5, 2022SPHERE Per-AF will determine the safety and effectiveness of the Sphere-9 cardiac ablation and mapping catheter with the Affera mapping and navigation system DUBLIN, Dec. 5, 2022 /PRNewswire/ --...
-
Nov 22, 2022
Earnings delivered despite slower market procedure volume and supply recovery; Growth driven by TAVR, Pacing, U.S. Core Spine, and International Diabetes DUBLIN, Nov. 22, 2022 /PRNewswire/ --...
-
Aug 30, 2022
Acquisition adds mapping and navigation platform to company's cardiac ablation portfolio and brings an integrated system of diagnostic and therapeutic tools to address a broad spectrum of arrhythmias
Aug 23, 2022Revenue exceeds guidance, with known supply chain challenges impacting results; notable strength in Pacing, Cardiac Surgery, Core Spine in the U.S., and Diabetes in Europe DUBLIN, Aug. 23, 2022...
May 26, 2022Mid-single digit FY22 revenue growth; Q4 results affected by temporary global supply chain impacts and China lockdowns DUBLIN, May 26, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today...
-
Feb 22, 2022
Company advanced its pipeline, launched new products, won share, and delivered earnings growth despite COVID-19 impact on healthcare procedure volumes DUBLIN, Feb. 22, 2022 /PRNewswire/ --...
-
Feb 18, 2022Family of focal ablation catheters are the first and only to treat specific type of supraventricular tachycardia (SVT)
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the Freezor™ and Freezor™ Xtra Cardiac Cryoablation Catheters are approved by the U.S. Food and Drug...
-
Jan 10, 2022
Acquisition to expand company's cardiac ablation portfolio, including first-time entry into mapping and navigation, within one of the fastest growing medtech markets DUBLIN, Jan. 10, 2022...
Nov 23, 2021Company continued to launch new products, win share, and deliver strong earnings growth; market procedure volumes impacted by COVID-19 resurgenceMedtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2022, which ended October 29, 2021. Key Highlights Revenue of $7.8 billion increased 3% reported...
-
Nov 4, 2021
New data from Medtronic Patient Preference study presented at TCT 2021; Medtronic adds to its clinical leadership for renal denervation with launch of the SPYRAL AFFIRM study DUBLIN and ORLANDO,...
-
Sep 7, 2021
Results Demonstrate Feasibility of Bronchoscopic Microwave Ablation for Certain Patients with Malignant Lung Nodules DUBLIN, Sept. 7, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global...
Aug 24, 2021Strong Financial Performance on Continued Procedure Volume Recovery and Share Gains from New Product LaunchesMedtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2022, which ended July 30, 2021. Key Highlights Revenue of $8.0 Billion Increased 23% Reported and...
-
Jun 21, 2021
- First and Only Approval to Indicate Cryoablation as an Initial Rhythm Control Strategy - Offers Safe, Effective Alternative to Antiarrhythmic Drug Therapy for the Prevention of Atrial Arrythmia...
-
May 27, 2021- Q4 Revenue of $8.2 Billion Increased 37% Reported and 32% Organic
Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year 2021, which ended April 30, 2021. The company reported fourth quarter worldwide revenue of $8.188...
-
Apr 27, 2021
Minimally Invasive Option Has Potential to Provide Long-Term Management of Lung Malignancies While Protecting Lung Function DUBLIN, April 27, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the...
-
Mar 4, 2021
Study Will Determine the Safety and Effectiveness of Pulsed Electrical Fields to Interrupt Irregular Heart Rhythms DUBLIN, March 4, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global...
-
Jan 29, 2021Clinical Trial Demonstrates Procedural Efficiencies, Safety, Effectiveness and Non-Inferiority of DiamondTemp System
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval of the DiamondTemp™ Ablation (DTA) system...
Dec 15, 2020The OPuS One Clinical Study is the largest study with the most meaningful clinical results supporting the OsteoCool™ Technology to-dateMedtronic plc (NYSE: MDT) today announced the release of outcomes in the first 100 patients treated with the OsteoCool™ Radiofrequency Ablation (RFA) System in the OPuS One Clinical Study (as...
-
Nov 24, 2020
- Q2 Revenue of $7.6 Billion Decreased 0.8% Reported and 1.5% Organic - Q2 GAAP Diluted EPS of $0.36; Q2 Non-GAAP Diluted EPS of $1.02 DUBLIN, Nov. 24, 2020 /PRNewswire/ -- Medtronic plc...
-
Nov 16, 2020Results from Three Studies Show Medtronic Cryoablation is Superior to Drug Therapy for First-Line Treatment
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the primary results of the Medtronic-sponsored STOP AF First clinical trial have been published in the New...
-
Oct 14, 2020
Company Raises Revenue Growth Outlook Highlights Deep and Broad Pipeline and Technology Platforms DUBLIN, Oct. 14, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical...
-
Aug 29, 2020ESC Congress: New Research Highlights First-Line Use of Cryoablation as Highly Effective, and with Improved Quality of Life Scores
DUBLIN, Aug. 29, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced clinical trial results demonstrating superiority of the Arctic Front™...
-
Aug 25, 2020Q1 Revenue of $6.5 Billion Decreased 13% Reported and Approximately 17% Organic
DUBLIN, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2021, which ended July 31, 2020. The company reported...
-
Feb 4, 2020SPYRAL DYSTAL Study to Evaluate the Effects of RDN Using Fewer, Targeted Ablations to Achieve Meaningful Blood Pressure Reductions
DUBLIN, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced it will begin enrollment in a pilot study evaluating the safety and efficacy of the Symplicity™ Spyral renal...
-
Jan 23, 2020Investigative Technology Designed to Interrupt Irregular Pathways in the Heart
DUBLIN, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced that it received approval from the U.S. Food and Drug Administration (FDA) to proceed with an investigational...
-
Nov 19, 2019Revenue of $7.7 Billion Increased 3.0% Reported and 4.1% Organic
DUBLIN, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2020, which ended October 25, 2019. The company reported...
-
Aug 20, 2019Revenue of $7.5 Billion Increased 1.5% Reported; Increased 3.5% Constant Currency
DUBLIN, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2020, which ended July 26, 2019. The company reported...
-
Apr 17, 2019
(GLOBE NEWSWIRE via COMTEX) --DUBLIN and LONDON - April 17, 2019 - Medtronic plc (NYSE:MDT) today announced five-year outcomes from the VeClose Extension Study. Nick Morrison, M.D., Center for...
-
Feb 27, 2019Medtronic Expands Pain Portfolio with Minimally Invasive Therapy to Support Patients Throughout the Care Continuum
DUBLIN - February 27, 2019 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Accurian(TM) RF ablation platform, which conducts radio...
-
Jan 30, 2019Company Is Committed to Leading Evidence Generation Across the Lung Cancer Care Continuum
DUBLIN - January 30, 2019 - Medtronic plc (NYSE:MDT) today announced that the Journal of Thoracic Oncology has published 12-month results of the NAVIGATE study, the largest, prospective,...
-
Jan 24, 2019
(GLOBE NEWSWIRE via COMTEX) --DiamondTemp Ablation System Represents Disruptive RF Innovation DUBLIN - January 24, 2019 - Medtronic plc (NYSE: MDT) today announced that it has entered into a...
-
Dec 3, 2018Study Will Evaluate Simultaneous Use of Radiofrequency and Cryo Surgical Ablation Devices in Cardiac Surgery Patients with Atrial Fibrillation
DUBLIN - December 3, 2018 - Medtronic plc (NYSE:MDT) today announced the first patient treated in the TERMINATE AF trial, a multi-center study evaluating two surgical ablation devices - the...
-
Nov 20, 2018Revenue of $7.5 Billion Increased 6.1% Reported; Increased 7.5% Organic
DUBLIN - November 20, 2018 - Medtronic plc (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2019, which ended October 26, 2018. The company reported second...
-
Aug 28, 2018
(GLOBE NEWSWIRE via COMTEX) --Clinical Trial Data Presented at European Society of Cardiology in Munich DUBLIN and MUNICH - August 28, 2018 - Medtronic plc (NYSE:MDT) today announced new findings...
-
Aug 21, 2018(GLOBE NEWSWIRE via COMTEX) --- Revenue of $7.4 Billion Decreased 0.1% Reported; Increased 6.8% Organic
DUBLIN - August 21, 2018 - Medtronic plc (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2019, which ended July 27, 2018. The company reported first quarter...
-
May 24, 2018Q4 Revenue of $8.1 Billion Grew 2.9% Reported and 6.5% Organic
DUBLIN - May 24, 2018 - Medtronic plc (NYSE: MDT) today announced financial results for its fourth quarter and fiscal year 2018, which ended April 27, 2018. The company reported fourth quarter...
-
Apr 17, 2018Product Line Offers Unique, Resorbable Option for Patients with Hypervascular Tumors
DUBLIN - April 17, 2018 - Medtronic plc (NYSE: MDT) today announced its U.S. launch of OptiSphere(TM) embolization spheres, a resorbable embolic platform designed for embolization of hypervascular...
-
Apr 10, 2018
DUBLIN - April 10, 2018 - Medtronic plc (NYSE: MDT) announced today the CE (Conformité Européenne) Mark and European launch of the Visualase(TM) MRI-Guided Laser Ablation System. The Visualase...
-
Mar 19, 2018
DUBLIN and BARCELONA, Spain - MARCH 19, 2018 - Medtronic plc (NYSE: MDT) today announced one-year results from the CRYO4PERSISTENT AF study of ablation with the Arctic Front Advance(TM)...
-
Feb 20, 2018Revenue of $7.4 Billion Increased 1% as Reported; 7% at Comparable, Constant Currency
DUBLIN - February 20, 2108 - Medtronic plc (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2018, which ended January 26, 2018. The company reported third quarter...
-
Nov 21, 2017Revenue of $7.1 Billion; GAAP Diluted EPS of $1.48; Non-GAAP Diluted EPS of $1.07
DUBLIN - November 21, 2017 - Medtronic plc (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2018, which ended October 27, 2017. The company reported second...
-
Aug 28, 2017Published Simultaneously in The Lancet, the Late-Breaking SPYRAL HTN-OFF MED Study at ESC Successfully Isolates RDN Treatment Effect to Show Compelling Efficacy and Safety of Hypertension Procedure
DUBLIN and BARCELONA - August 28, 2017 - Medtronic plc (NYSE:MDT) today announced its intent to move forward with a new renal denervation pivotal trial following positive first results from a...
-
Aug 1, 2017Data from Landmark Trial Published in the Journal of the American Heart Association
DUBLIN - August 1, 2017 - A new health economic analysis from the landmark FIRE AND ICE Trial, sponsored by Medtronic plc (NYSE: MDT), was published today in the Journal of the American Heart...
-
Jul 11, 2017
DUBLIN - July 11, 2017 - Medtronic plc (NYSE: MDT) today announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the safety and effectiveness of performing...
-
Apr 25, 2017Three-Year VeClose Trial and One-Year WAVES Study Data Presented at Charing Cross
DUBLIN and LONDON - April 25, 2017 - Medtronic plc (NYSE: MDT) today announced three-year outcomes from the VeClose U.S. pivotal clinical trial and one-year data from the WAVES study. Both results...
-
Apr 20, 2017New Data from the Global ENGAGE Registry, IN.PACT Admiral Global Study, and VeClose Study Among Key Presentations
LONDON and DUBLIN - April 20, 2017 - Medtronic plc (NYSE: MDT) today announced key clinical studies for its leading vascular interventional portfolio will be featured at the annual 2017 Charing...
-
Mar 30, 2017
DUBLIN - March 30, 2017 - Medtronic plc (NYSE: MDT) today announced first enrollments in the STOP Persistent AF clinical trial. The trial will evaluate the safety and effectiveness of a pulmonary...
-
Feb 16, 2017New Single-Handed Powered Stapling System Provides Real-time Feedback During Surgery1
DUBLIN - Feb. 15, 2017 - Medtronic plc (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded indication for the OsteoCool(TM) RF Ablation System....
-
Jan 24, 2017
DUBLIN - Jan. 24, 2017 - Medtronic plc (NYSE: MDT) announced today that the first procedure using the Visualase(TM) MRI-Guided Laser Ablation System has been performed in the pivotal SLATE...
-
Oct 13, 2016Late Breaking Clinical Trial Demonstrates Favorable Health Economics and Positive Clinical Outcomes for AF Patients
DUBLIN AND SEOUL, REPUBLIC OF KOREA - Oct. 13, 2016 - Medtronic plc (NYSE:MDT) today unveiled new health economic analysis data from the FIRE AND ICE trial that favor cryoballoon catheter ablation...
-
Sep 12, 2016Clinical Practice Guidelines from European Society of Cardiology 2016 Reinforce Benefits of Cryoballoon Ablation and Long-Term Cardiac Monitoring
DUBLIN - September 12, 2016 - Two Medtronic plc (NYSE: MDT) innovations were acknowledged in updated guidelines published by the European Society of Cardiology (ESC): cryoballoon ablation for...
-
Jun 17, 2016Drug-Resistant Mesial Temporal Lobe Epilepsy Is the Focus of Medtronic's SLATE Study
DUBLIN - June 17, 2016 - Medtronic plc (NYSE: MDT) announced today the U.S. Food and Drug Administration's (FDA) approval of the Investigational Device Exemption (IDE) application for the pivotal...
-
Jun 10, 2016Secondary Analyses Presented at Cardiostim 2016 Highlight Positive, Real-World Patient Outcomes
DUBLIN AND NICE, FRANCE - June 10, 2016 - Medtronic plc (NYSE: MDT) today announced findings from the secondary analyses of the FIRE AND ICE clinical trial that demonstrate significantly fewer...
-
May 18, 2016
DUBLIN - May 18, 2016 - Medtronic plc (NYSE: MDT) today announced it has signed a definitive agreement to acquire Smith & Nephew's (NYSE: SNN; LSE: SN) gynecology (GYN) business for approximately...
-
Apr 21, 2016BarrxTM 360 Express RFA Balloon Catheter's Adjustable Custom Fit Provides Targeted Precision Therapy - Allowing Physician Ease and Efficiency
DUBLIN - April 21, 2016 - Medtronic (NYSE: MDT) today announced the launch of the new BarrxTM 360 Express radiofrequency ablation (RFA) balloon catheter, which can help in the treatment of...
-
Apr 8, 2016Medtronic Unveils Data for VenaSeal Closure System at Charing Cross and the International Vein Congress
DUBLIN - April 28, 2016 - This week at the 2016 Charing Cross Symposium in London and the International Vein Congress in Miami, Medtronic plc (NYSE: MDT) unveiled clinical data for the...
-
Apr 4, 2016Cryoballoon Comparable in Safety and Effectiveness as Current Standard of Care Ablation Technology
DUBLIN and CHICAGO - April 4, 2016 - Medtronic plc (NYSE: MDT) today announced positive results from the landmark FIRE AND ICE clinical trial, which demonstrated comparable safety and...
-
Jan 13, 2016Minimally-Invasive Procedure Brings Relief to Patients Suffering from Painful Spine Tumors
DUBLIN - January 13, 2016 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and U.S. launch of the OsteoCool(TM) RF Ablation System. For...
-
Dec 14, 2015Live On. Give On: Medtronic Philanthropy Provides MedTech Patients with $20,000 Grant to Direct to a Charitable Cause of Their Choice
DUBLIN - December 14, 2015 - Medtronic (NYSE: MDT) announced today that 12 people representing 11 countries will be honored with the 2015 Bakken Invitation Award, which recognizes people who have...
-
May 12, 2015Third-Generation Cryoballoon Designed to Allow Enhanced Positioning and Help Improve Capture of Real-Time Data with Achieve® Mapping Catheter
DUBLIN - May 12, 2015 - Medtronic plc (NYSE: MDT) today announced the Arctic Front Advance® ST Cryoablation Catheter has received U.S. Food and Drug Administration (FDA) approval for the...
-
Nov 18, 2014Revenue of $4.4 Billion Grew 5% on Constant Currency Basis; 4% as Reported
MINNEAPOLIS - Nov. 18, 2014 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2015, which ended October 24, 2014. The company reported worldwide...
-
Nov 13, 2014Data Demonstrate Strong Closure Rates in Patients with Chronic Venous Insufficiency, Varicose Veins
DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 13, 2014-- Covidien plc (NYSE:COV) today announced the six-month results of the VeClose pivotal study, which demonstrated the safety and effectiveness of the...
-
Nov 2, 2014Expands Spectranetics' portfolio of solutions to treat complex vascular conditions in projected $700 million drug coated balloon segment
COLORADO SPRINGS, Colo., and DUBLIN, Ireland, Nov. 2, 2014 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) and Covidien plc (NYSE:COV) today announced a definitive agreement under...
-
Aug 19, 2014Revenue of $4.3 Billion Grew 4% on Constant Currency Basis; 5% as Reported
MINNEAPOLIS - Aug. 19, 2014 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2015, which ended July 25, 2014. The company reported worldwide...
-
Jul 28, 2014MRI-Guided Laser Ablation Technology Adds to Surgical Technologies Product Portfolio and Broader Neuroscience Leadership Positi
MINNEAPOLIS - July 28, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that it has completed the acquisition of Visualase, Inc., a privately held company based in Houston, TX, that develops and...
-
Jul 25, 2014Net sales up 4%; Medical Devices sales up 5%
DUBLIN, Ireland--(BUSINESS WIRE)--Jul. 25, 2014-- Covidien plc (NYSE: COV) today announced financial results for the third quarter of fiscal 2014. Third-quarter net sales of $2.69 billion...
-
Jul 16, 2014Emprint™ Ablation System enables more certainty regardless of target location or tissue type
DUBLIN, Ireland--(BUSINESS WIRE)--Jul. 16, 2014-- Overcoming a significant roadblock to predictable ablation of soft tissue, Covidien plc (NYSE:COV) has unveiled an advanced ablation system that...
-
Mar 25, 2014
DUBLIN--(BUSINESS WIRE)--Mar. 25, 2014-- An innovative Covidien (NYSE: COV) technology is effective at treating Barrett’s esophagus (a precancerous condition of the esophagus), according to a...
-
Jan 6, 2014
MINNEAPOLIS - Jan. 6, 2014 - Medtronic, Inc. (NYSE:MDT) today announced the first patient has been enrolled in the VICTORY AF clinical trial, a prospective, non-randomized, controlled study of...
-
Dec 5, 2013
Thomson Reuters ONE via COMTEX) --Multi-Electrode System Built Upon Clinical Success and Strong Safety Profile of Single-Electrode Symplicity(TM) Renal Denervation System MINNEAPOLIS -- December...
-
May 21, 2013Initial Results from Feasibility Study of the Symplicity Spyral(TM) Catheter Show Safety and Efficacy While More than Halving Mean Procedure Time
MINNEAPOLIS and PARIS - MAY 21, 2013 - Medtronic, Inc. (NYSE: MDT) announced today preliminary results from the feasibility study of its Symplicity SpyralTM multi-electrode, 6 Fr renal denervation...
-
Jan 15, 2013Second-Generation Sheath May Facilitate Easier Access to the Inferior Veins When Treating Paroxysmal Atrial Fibrillation
MINNEAPOLIS - Jan. 15, 2013 - Medtronic, Inc. (NYSE: MDT) today announced Food and Drug Administration (FDA) clearance and U.S. launch of the FlexCath Advance(TM) Steerable Sheath, a new...
-
Aug 24, 2012Next-Generation Technology Reinforces Safety and Efficacy While Improving Procedure Efficiency
MINNEAPOLIS – Aug. 24, 2012 – Medtronic, Inc. (NYSE:MDT) today announced that its Arctic Front Advance™ Cardiac Cryoballoon has received both U.S. Food and Drug Administration (FDA) approval...
-
Mar 15, 2012Another Medtronic First in Neuromodulation in Canada
BRAMPTON, Ontario & MINNEAPOLIS--(BUSINESS WIRE)--Mar. 15, 2012-- Medtronic, Inc. (NYSE: MDT) today announced that it has received from Health Canada a license for Medtronic Deep Brain Stimulation...
-
Jan 24, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 24, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the first patient was enrolled in the FIRE AND ICE clinical trial, which is a prospective, randomized,...